Abatacept biosimilar (Hanwha Biologics)

阿巴西普生物类似药 (Hanwha Biologics)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAbatacept biosimilar (Hanwha Biologics)

Drug Alias Name阿巴西普生物仿制药 (Hanwha Biologics)

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein

Mechanisms of ActionCluster of differentiation 86 inhibitorsCluster of differentiation 80 inhibitors

TargetsCluster of differentiation 80Cluster of differentiation 86

Therapy Area/IndicationsArthritis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Clinical)

Highest Status in ChinaN/A

Originator CompaniesHanwha Biologics

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesHanwha Biologics

Active IndicationsN/A

Inactive IndicationsArthritis

ATC CodeL04AA24